Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "VAI"

1900 News Found

Medanta launches 550-bed super speciality hospital in Noida
Hospitals | November 28, 2025

Medanta launches 550-bed super speciality hospital in Noida

The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs


FDA updates label for Sun Pharma’s UNLOXCYT, highlighting durable responses in advanced skin cancer
Clinical Trials | November 27, 2025

FDA updates label for Sun Pharma’s UNLOXCYT, highlighting durable responses in advanced skin cancer

The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses


Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response
Clinical Trials | November 27, 2025

Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response

Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020


NHS’s breakthrough leukaemia therapy set to transform lives in UK
Clinical Trials | November 27, 2025

NHS’s breakthrough leukaemia therapy set to transform lives in UK

Clinical trials found that 77% of patients went into remission after receiving obe-cel


Bengaluru makes medical history with first robot-assisted deceased donor kidney transplant
Hospitals | November 26, 2025

Bengaluru makes medical history with first robot-assisted deceased donor kidney transplant

Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically


Novartis scores FDA nod for game-changing SMA treatment
Biotech | November 26, 2025

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA


Moderna bags $1.5 billion 5-Yr loan to boost financial flexibility
News | November 24, 2025

Moderna bags $1.5 billion 5-Yr loan to boost financial flexibility

The non-dilutive financing includes three tranches


Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi
Drug Approval | November 24, 2025

Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi

Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis